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1. Introduction  
Pharmacogenetics uses genetic information to help adjusting treatment for individual 
patients. It improves efficacy of therapy and enables avoiding side effects basing on 
genetic knowledge. Different asthmatic patients with similar disease severity, who are 
treated with the same medication, may respond to the therapy differently. After excluding 
non-genetic causes of such variability (like patient’s compliance, environmental and 
psychological factors), the most possible reason for the variability appears to be a 
different genetic structure. Changes in gene structure resulting in inter-individual 
dissimilarities, occur mostly as single nucleotide polymorphism (SNP). Different 
strategies play a role in searching and identifying SNPs, that influence pathogenesis of 
asthma and its response to treatment, (Kazani et al., 2010). One of the strategies involved 
is candidate gene studying, that focuses on finding genes responsible for therapy 
effectiveness as well as asthma development and its clinical severity (Moffatt & Cookson, 
1997). Pharmacogenetics of asthma concentrates on genes coding: drug binding receptors, 
enzymes (important both in drug metabolism and metabolic cycles, eg. arachidonic acid 
cascade), chemokines, cytokines or growth factors relevant to asthma pathogenesis and 
pathophysiology. Genes need to be studied for known SNPs and new variants as well. 
When an SNP is found a thorough check for possible correlation between this 
polymorphism and disease phenotype or treatment response is needed. An expanded 
strategy for searching candidate genes involves screening of genes encoding proteins 
(enzymes) active in metabolic cycles important for drug response or key disease 
pathologies. In asthmatic patients this last method is often used to examine the 
leukotriene pathway in order to elucidate different patient reactions to leukotriene 
modifiers. Other options are genome-wide association studies that analyze genetic 
markers across the entire genome that may be connected with the phenotype. The 
identification of such a marker generated investigation of surrounding genes for SNPs 
related to the phenotype (Kazani et al., 2010). This procedure needs numerous and 
phenotypically well characterised populations and enables examination of the most 
frequent SNPs. There are some fields of medicine where pharmacogenetics is already in 
clinical use but in asthma treatment further investigation is still needed. This chapter 
reviews recent knowledge of pharmacogenetics of drugs commonly used in asthma 
treatment. We focus on bronchodilators, iCS (inhaled corticosteroids) and leukotriene 
modifiers.  
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2. Pharmacogenetics of antiasthmatic medications 
2.1 Pharmacogenetics of β2-agonists 
ǃ2-adrenoreceptor (ǃ2-ADR) agonists are fundamental relief medications and among the 
most important chronic treatments in asthma. These drugs exert their action by activation 
of ǃ2-adrenoreceptors located among others on smooth muscle cells. This results in 
smooth muscle relaxation, airway dilatation and improved airflow. Depending on the 
duration of their action ǃ2-agonistss are divided into two groups: short acting (SABA) and 
long acting ǃ2-agonists (LABA). SABA are used exclusively as rescue medicines. They 
quickly reduce asthma symptoms: wheezing, shortness of breath and coughing. While 
LABA when used on a daily basis in combination with iCS help to improve asthma 
control. The side effects are common for both groups and these are: tachycardia, muscle 
tremble, mild hypokalaemia.  
The ǃ2-adrenoreceptor is a member of the 7-transmembrane domain G-protein coupled 
receptor family. It consists of seven transmembrane spanning domains, 3 extracellular and 3 
intracellular (Fig. 1) (Dixon et al., 1986). Stimulation of ǃ2-adrenoreceptor is G-protein 
dependent and results in activation of the second messenger, the adenylate cyclase. This in 
turn leads to an increase of cAMP level and smooth muscle relaxation. Another mechanism 
resulting from ǃ2-adrenoreceptor stimulation is potassium channels opening by cAMP or 
directly by G-protein (Kowalski & Woszczek, 2002).  
 
Fig. 1. Most common clinically relevant polymorphisms of the ǃ2-adrenoreceptor (Ligget, 1997- 
changed). Black - nucleic acid deviations from wild type not resulting in nucleotide changes. 
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2.1.1 Polymorphisms of the β2-adrenergic receptor 
Examination of the intronless ǃ2-adrenoreceptor gene, which is located on chromosome 
5q31.32 (Kobilka et al., 1987), revealed over 80 SPNs (Weiss et al., 2006). Two of these 
polymorphisms: Arg→Gly16 (46A→G) and Gln→Glu27 (79C→G) are the most frequent 
ones (see Figure 1.) (Green et al.,1994, 1995; Lee et al., 2004). Their occurrence results in 
receptor function change, different ligand binding and impaired signal transmission. The 
occurrence of the Gly16 gene variant is higher than that of the wild-type Arg16 and ranges 
between 67% in British asthmatics and 72% in British and American healthy subjects 
(Liggett, 1997; Tan et al., 1997; Lipworth et al., 1999). It has been estimated that the 
homozygous genotype Arg16 appears in 16% Caucasians and 25% Afro-Americans. Studies 
of Xie (Xie, et al., 2001) and co-workers revealed further differences between ǃ2-
adrenoreceptor polymorphisms and ethnic groups. In a study, that examined 415 healthy 
subjects, Glu27 allele were the most frequent in Caucasian-Americans (34.8%). Other groups 
had much lower occurrence of this allele: Afro-Americans (20.7%) and Chinese (7.2%). 
Individuals with homozygous Glu27 genotype were mostly Caucasian-Americans (15.4%). 
This genotype occured only in  4.9% African-Americans and was not observed in Chinese 
subjects (Xie, et al., 2001). Both Gly16 and Glu27 polymorphisms are involved in higher 
agonist promoted receptor down-regulation, moreover, Glu27 is related with a stronger 
desensitization of the receptor (Green et al., 1994, 1995). Another defined polymorphism: 
Thr→Ile164 is associated with diminished affinity of ǃ2-agonist to the receptor, decreased 
adenylate cyclase binding and 50% shorter lasting salmeterol (one of the long acting beta2 
agonists) effect (Green et al., 2001).  
2.1.1.1 Correlation between β2-adrenoreceptor gene polymorphism and short acting  
β-agonists action 
Short acting ǃ-agonists are drugs commonly used in asthma treatment, especially in 
asthma exacerbations or as regular rescue medications. However, they are not 
recommended as regular antiasthmatic drugs. Several studies demonstrated higher FEV1 
increase (forced expiratory volume in the first second, a spirometric parameter used to 
determine the level of airways narrowing) increase after SABA (salbutamol) 
administration in homozygous Arg16 individuals as compared to heterozygous and 
homozygous Gly16 patients with polynosis (Martinez et al., 1997; Woszczek et al., 2005). 
Different results were obtained during asthma exacerbation. Patients who were 
homozygous Arg16 had impaired SABA response compared to homozygous Gly16 
individuals (Carroll et al., 2009). Systematic administration of SABA to Arg16 asthmatics 
caused deterioration of lung function (as evaluated with PEF - peak expiratory flow, 
another parameter used to monitor airway narrowing), that did not stop even with 
treatment discontinuation. In contrast patients homozygous for Gly16 demonstrated 
improved lung function (evaluated by PEF measurement as well) (Israel, 2000, 2004). 
Based on these studies it has been postulated that Arg16 homozygotes may be at higher 
risk during long-term SABA therapy. According to the 2010 updated GINA guidelines  
(Global Initiative for Asthma [GINA], 2010) regular long-term SABA treatment is not 
recommended for any individual. But due to relatively low differences in PEF-worsening 
between the two groups more research is needed to fully elucidate this problem.   
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2.1.1.2 Correlation between β2-adrenoreceptor gene polymorphisms and long acting  
β-agonists action 
Long acting ǃ2-agonists as opposed to SABA are drugs commonly used in long-term asthma 
therapy. There are several population studies suggesting increased risk of therapy with long 
acting ǃ2-agonists in patients with the Arg16 homozygous genotype. However, no genotype 
is currently considered a direct contraindication for LABA treatment. Some patients treated 
with salmeterol, experienced rare but severe asthma exacerbations (Nelson et al., 2006). 
Further investigation suggested a dependence between Arg16 genotype and faster decline of 
lung parameters (FEV1) after LABA application (Nelson et al., 2006; Wechsler et al., 2006; 
Lee et al., 2004; Palmer et al., 2006). A good example is a study of Wechsler and co-workers 
comparing salmeterol response in individuals with asthma homozygous for arginine 
(Arg16) with glycine homozygous (Gly16) group of patients. Patients were divided in two 
groups . The first group was treated with salmeterol without iCS and the second continued 
iCS therapy while randomized for salmeterol. In both groups Arg16 patients didn’t draw 
benefit from salmeterol therapy comparing to Gly16 patients, which resulted in lower 
morning PEF, increased symptom scores and albuterol rescue use especially in trial without 
iCS. Present asthma treatment guidelines allow use of LABA only together with iCS since it 
has been demonstrated that iCS ameliorate the LABA effect. It is possible that in the future 
patients with Arg16Arg genotype will constitute a group requiring different treatment 
guidelines, but up to date therapeutic indications are uniform irrespective of the patient’s 
genotype.     
2.1.1.3 Correlation between β2-adrenoreceptor gene polymorphisms and asthma 
exacerbations 
It has been proven that exacerbations of asthma during short acting ǃ-agonist therapy is 
related to ǃ2-adrenoreceptor gene polymorphisms (Taylor et al., 2000). Recent studies 
reveal, that children and adolescent asthmatics with the Arg16 genotype suffer from asthma 
exacerbations more frequently than the Gly16 subpopulation (OR 2.05, 95% CI 1.19 to 3.53, 
p=0.010). This genotype-exacerbation correlation significantly increases after salmeterol 
treatment (OR 3.40, 95% CI 1.19 to 9.40, p=0.022) (Palmer et al., 2006). Other studies confirm 
the conclusion that risk of asthma exacerbation in the Arg16 group rises with higher doses 
and more frequent use of ǃ2-agonists. Individuals with the Arg16 genotype receiving short- 
or long-acting ǃ2-agonists on everyday basis had significantly higher risk of asthma 
exacerbation (OR 1.64, 95% CI 1.22 to 2.20, p=0.001) than patients with the Arg16 genotype 
taking ǃ2-agonist less than once daily (Basu et al., 2009). According to the LARGE study 
patients with the Gly16 genotype have diminished bronchial  hyperresponsiveness to 
matacholine after adding inhaled corticosteroids (at an average dose 480µg of 
beclomethasone daily) to salmeterol treatment (Wechsler et al., 2009). Arg16 genotype Afro-
Americans have a lower chance for lung function improvement after co-administration of 
LABA and inhaled corticosteroids what may be related to more frequent prevalence of 
Arg16 polymorphism in this population (25%). This can also explain ethnic differences in 
asthma manifestation – more frequent severe asthma occurrence in Afro-Americans. 
According to Liggett (Liggett, SB., 2000) ǃ2-adrenoreceptors in Gly16 subjects are down 
regulated at baseline by exposure to endogenous cathecholamines what explains why 
reaction to exogenous ǃ2-agonists is more evident in Arg16Arg individuals. At the same 
time however, Arg16 patients seem to have higher risk of asthma exacerbation especially 
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during ǃ2-agonist therapy. Despite these differences present guidelines [GINA, BTS (British 
Thoracic Society)] do not recommend checking the patients’ genotype before starting 
therapy. In our opinion LABA-treatment failure should be a recommendation for ǃ2-
adrenoreceptor genotype verification. This may increase both treatment effectiveness and 
safety. More research in this field is needed, however.         
2.2 Pharmacogenetics of leukotriene modifiers 
Leukotrienes are a family of polyunsaturated eicosatetraenoic acids that are derived from 
arachidonic acid in an enzymatic pathway called arachidonic acid cascade (see Figure 2.). In 
this pathway 5-lipoxygenase plays probably the most important role (Dixon et al., 1990). 5-
lipoxygenase (5-LOX) catalyzes the conversion of arachidonic acid to leukotriene-A4 (LTA4) 
(Silverman & Drazen, 1999). All leukotrienes include cysteine and are called cysteinyl 
leukotrienes (with the exception of LTB4). Cysteinyl leukotrienes bind to CysLT1 receptor 
causing among others airway smooth muscle contraction, eosinophilic influx and mucus 
hypersecretion. Another important enzyme in the leukotriene pathway is LTC4 synthase, 
which is responsible for LTA4 to LTC4 conversion. Leukotrienes have been shown to be 
potent pro-inflammatory mediators in asthma pathology (Chanarin & Johnston, 1994). They 
are produced and released by several types of inflammatory cells including eosinophils, 
neutrophils and mast cells.  
 
 
Fig. 2. The lipoxygenase pathway of leukotriene synthesis 
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Leukotriene modifiers are an important group of drugs in asthma treatment as well as in 
other diseases including allergic rhinitis. Based on their mode of action they can be divided 
into two groups: first – cysteine leukotrienes receptor antagonists (montelukast, zafirlukast, 
pranlukast and tomelukast), second - 5-lipoxygenase inhibitors (zileuton). These drugs show 
strong anti-inflammatory activity, ameliorate asthma clinical course and improve disease 
control with minimal or no side effects. Currently, they are listed in GINA 2010 (GINA, 
2010) guidelines for asthma treatment as number two anti-inflammatory treatment (number 
one are still inhaled steroids), even though not all asthmatic patients benefit substantially 
from anti-leukotriene therapy. Based on the knowledge on leukotriene synthesis pathway, 
studies of genotype dependent therapeutic reactions have used strategies of candidate gene 
screening and examination of SNPs in genes encoding different proteins (enzymes) of the 
arachidonic acid cascade. To date, most investigations of the genetic factors which may 
affect therapy with anti-leukotriene drugs have focused on the 5-LOX enzyme and the LTC4 
synthase. Possible genetic alterations of cysteine leukotriene receptors have also been 
investigated. The following paragraphs discuss the most important pharmacogenetic studies 
presenting major polymorphisms relevant in asthma and allergy as well as their impact on 
drug action. 
2.2.1 Polymorphisms of the 5-lipoxygenase gene 
The 5-LOX gene (ALOX5) is located on chromosome 10q11.12, contains 14 exons and its 
activity is associated with a number of repetitions of Sp1/Erg1 binding motifs in the 
promoter region (Hoshiko et al., 1990; Funk et al., 1989; Silverman et al., 1998). The promoter 
region containing five tandem motifs binding Sp1/Erg1 transcription factors (GGGCGG) is 
known as wild-type allele (Silverman et al., 1998). Polymorphisms of this region result from 
additions or deletions of binding motifs and are called non-wild-type alleles (In et al., 1997; 
Silverman et al., 1998). A polymorphism with one additional Sp1/Erg1 binding motif has 
been found in 35% of both asthmatic and non-asthmatic population (Fenech, A & Hall, IP., 
2002). Further, 3% of the subjects without any copy of a wild-type allele are expected to have 
lower ALOX-5 gene transcription, which leads to reduced enzyme production and finally to 
lower LTA4 levels (Drazen et al., 1999; Kalayci et al., 2003). In consequence, the low level of 
cysteinyl leukotriene does not intensify allergic inflammation in asthma, but patients who 
do not have a wild-type allele, experience only 1% FEV1 improvement after 5-LOX inhibitor 
treatment comparing to wild-type patients (FEV1 improves up to 15-20%) and are 
considered non-responders for this type of therapy (Drazen et al., 1999). The same concerns 
to montelukast treatment (antagonist of cysteine leukotriene receptors): wild-type 
homozygous and heterozygous patients present benefit greatly from treatment (measured 
as FEV1 improvement (Telleria et al., 2008)), while non-wild-type are considered relative-
non-responders. Other studies demonstrated however, that subjects with non-wild-type 
allele(s) treated with montelukast had reduced (73%) risk of asthma exacerbation (Lima et 
al., 2006). Because the role of leukotriene modifiers in asthma control increased significantly 
in the past five years, further studies are necessary to define responders and non-responders 
phenotypes. Defining standards of responding to leukotriene modifier therapy is extremely 
important at least in two subpopulations: in non-wild-type individuals, who in previous 
tudies have not experienced treatment benefit and in patient with steroid resistance or at 
least with partially impaired response to iCS.  
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2.2.2 Polymorphisms of the leukotriene C4 synthase gene (LTC4S) 
LTC4 synthase (LTC4S) belongs to S-glutathione synthases family and is responsible for 
leukotriene A4 and glutathione bonding. This reaction results in leukotriene C4 synthesis. 
LTC4 is a potent contractor of bronchial smooth muscles. The gene for LTC4 synthase is 
located on chromosome 5q35. In the promoter region of this gene several polymorphism 
have been described. One of the most important is substitution of nucleotide A by C in 
position 444 (-444A→C). The -444A→C SNP results in increased LTC4S gene transcription 
and therefore higher LTC4 level in eosinophils (Sampson et al., 2000; Sanak et al., 2000). This 
variant occurs more often in patients suffering from aspirin induced asthma (in patients 
with aspirin idiosyncrasy in general) (Sanak et al., 1997). Presence of the C nucleotide is also 
related to better response to cysteine leukotriene receptor 1 (LTRA1) blockers. During 
montelukast therapy 80% reduction of asthma exacerbation risk was observed in 
heterozygous individuals with C allele when compared to AA homozygous (Lima et al., 
2006). Similar results were reported from a study in Japan, where patients with moderate, 
well controlled asthma, treated with inhaled corticosteroids, received pranlukast as an add-
on treatment. Again, individuals with the C allele had more pronounced FEV1 
improvement than AA homozygous patients (FEV1 improvement in C allele group 5.3% vs. 
in AA group 2.4%). Heterozygous population also showed higher values of bronchial 
dilatation after salbutamol usage (Asano et al., 2002).  
2.2.3 Polymorphisms of the cysteine leukotriene receptors 1 and 2 genes (CYSTLTR1, 
CYSTLTR2)  
The human CYSLT1 and CYSLT2 receptors have been characterized as G-protein coupled 
receptors (Lynch et al., 1999; Heise et al., 2000). The gene coding for the CYSLT1 receptor is 
located on chromosome X and the CYSTLT2 receptor gene maps to chromosome 13q14 
(Lynch et al., 1999; Heise et al., 2000). Polymorphisms of these genes are studied in relation 
to the probability of asthma development. Previous data suggest however, that 
polymorphisms of CYSTLTR1 and CYSTLTR2 genes play a minor role in the determination 
of asthma severity and clinical symptoms’ expression (alike other genes encoding proteins 
related to leukotriene pathway) (Tantisira & Drazen, 2009). As for now there are no 
unequivocal results concerning polymorphisms of the CYSLT receptor genes in relation to 
anti-leukotriene treatment effects.  
Although zileuton does not directly act through the CYSLT1 receptor, the possible 
correlation between this medication and CYSLT1R polymorphisms was also investigated. 
These studies, including genotype analysis of over five hundred patients treated with 
zileuton did not show any significant correlation between CYSLT1R gene polymorphisms 
and clinical response to therapy (Tantisira et al., 2009).  
2.2.4 Polymorphisms of the ABCC1 gene 
The ABCC1 gene (ATP-binding cassette, subfamily C, member 1) encodes MRP1 (Multiple 
Drug Resistance Protein 1) that takes a part in transmembrane LTC4 transport. This gene is 
located on chromosome 16p13.12 and demonstrates significant heterogeneity (Saito et al., 
2002; van der Deen et al., 2005). One of the polymorphisms of this gene, that was thought to 
be correlated to drug response,  namely rs119774, described by Lima et al. was related to a 
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significant FEV1 improvement in subjects receiving montelukast for 6 months (Lima et al., 
2006). Heterozygous patients had a 24% FEV1 rise as compared to only a 2% improvement 
in homozygous individuals (Lima et al., 2006). Since there are no further studies of this 
correlation available data are insufficient to have any treatment implications. Again, further 
studies would help to elucidate whether the two phenotypes differ enough to justify 
different treatment regimens.      
2.2.5 Polymorphism of LTA4 hydrolase gene 
Hydrolase LTA4 is an enzyme that converts LTA4 to LTB4. The gene encoding this protein 
is located on chromosome 12q22. One of the known polymorphisms for this gene 
(rs2660845) involves a nucleotide change A->G at intron. Patients, whose genotypes contain 
at least one G allele (heterozygous), when treated with montelukast, have 4-5 higher risk of 
asthma exacerbation when compared to AA homozygous subjects (Lima et al., 2006). The 
pathogenetic mechanism of this phenomenon remains unclear. It has been hypothesized 
that this SNP causes a decreased enzyme activity that results in diminished LTB4 synthesis, 
therefore stimulating the LTC4-synthase pathway and leading to cysteine leukotriene 
synthesis (Lima et al., 2006) (Fig. 2).  
There are big individual differences in response to leukotriene modifiers. All 
polymorphisms listed in paragraph 2.2 contribute to these differences. It remains extremely 
important to determine which patient subpopulation benefit most from the treatment.  
2.2.6 Polymorphisms of the SLCO2B1 gene 
The gene SLCO2B1 (solute carrier organic anion transporter family - 2B1) encodes the 
protein 2B1, that plays an important role in the active transport of organic anions through 
the intestinal wall. Protein 2B1 is thought to be a key transporter of montelukast through the 
intestinal wall. A recently described, common, SLCO2B1 polymorphism, namely rs12422149 
935G→A (Arg312Gln), appears to relate to changes in montelukast pharmacokinetics. 
Specifically, individuals with this SNP have a significantly lower serum drug concentration 
(Mougey et al., 2009). So far, there are no data on other possible SLCO2B1 gene 
polymorphisms that could affect montelukast transport or serum level. 
 
Gene  
Chromosomal 
location 
Polymorphisms with potential pharmacogenetic 
consequences during leukotriene modifier therapy  
ALOX5 10q11.12 
Promoter Sp1/Egr1binding motif  (G+C rich sequence, i.e. –
GGGCGG-) different than 5 sequence repeats, -212 to -88 bp 
LTC4S 5q35 Promoter -444A→C 
CYSLTR1 Xq13.2-q21.1 927C→T 
ABCC1 16p13.12  rs119774,  G→A intron 
LTA4H 12q22 rs2660845, A→G intron  
SLCO2B1 11q13 rs12422149 935G→A 
Table 1. Genes polymorphisms with potential pharmacogenetic consequences for 
leukotriene modifier therapy  
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Leukotriene modifiers are widely used in asthma treatment and they are orally 
administered which improves patients compliance and therefore efficacy. However, genes 
linked to their metabolism, drug-receptor interactions etc. have not intensively investigated. 
In our opinion, cytochrome P450, that metabolises both groups of leukotriene modifiers 
(especially CYP1A2 and CYP3A4), is a promising target. Studies investigating genetic 
variants of cytochrome P450 enzymes in relation to leukotriene modifiers response are 
necessary to establish possible dosing variations.   
2.3 Pharmacogenetics of inhaled corticosteroids (iCS) 
Corticosteroids are the most important and the most effective medication in asthma therapy. 
They are powerful anti-inflammatory agents in asthma management, mostly being “anti-
eosinophilic”. Although many asthmatics derive therapeutic benefit from inhaled 
corticosteroids, many fail to respond or at least need to be treated with much higher doses. 
Despite iCS being considered a safe treatment, side effects of increased dosage may be 
clinically significant and include: adrenal suppression, osteoporosis, skin changes, cataract, 
and growth retardation in children. There at least two different mechanisms of CS 
resistance, but both are still under investigation. 
Candidate gene studies were used to determine the pharmacogenetics of response to 
inhaled corticosteroids. 
2.3.1 Glucocorticoid receptor 
Corticosteroids exert their action by binding to the glucocorticoid intracellular receptor 
(GR), a nuclear receptor. The GR gene is located on the long arm of chromosome 5 (5q31-32). 
Members of the superfamily of nuclear receptors share a structural pattern containing a 
short central DNA-binding domain, a variable N-terminal domain as well as a C-terminal, 
which is the steroid hormone binding part, and a transcription regulator (Beato et al., 1996; 
Gronemeyer, 1992). There are two different GR isoforms known: one consisting of 777 
(called GRǂ) and the other of 742 amino acids called GRǃ. These isoforms are created during 
alternative splicing of the GR pre-mRNA (Bamberger et al., 1996). GRǃ varies from the other 
isoform only in the length of C-terminal domain, which is shorter by five amino acids. This 
results in reduced glucocorticoid binding affinity of the GRǃ receptor. Both receptors are 
expressed in all human cells, but GRǃ plays a regulatory role and its concentration is much 
lower than that of GRǂ. Although there is no evidence to support that this polymorphism is 
responsible for reduced responsiveness to GC in clinical practice, this concept has been 
widely discussed and related studies are currently carried out (Brogan et al., 1999; Gagliardo 
et al., 2000; Malmstrom et al., 1999). In the cytoplasm, the glucocorticoid receptor is linked 
with several regulatory proteins, with the heat shock protein (hsp90), p59 immunophilin 
and p23 phosphoprotein being the most important (Smith & Toft, 1993). GR and hsp90 
coupling enables ligand (CS) binding to the receptor and facilitates correct receptor 
“maturation” after synthesis (Smith & Toft, 1993). After CS binding the complex GR/hsp90 
is disunited and activated GR/CS translocates to the nucleus and binds to DNA via the 
central domain consisting of two “zinc fingers”(Mitchell & Tjian, 1989). On the DNA side 
the fragment interacting with GR is called GRE (glucocorticoid response elements). This is 
one of the two mechanisms for CS to stimulate or inhibit transcription and therefore mRNA 
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synthesis. The other mechanism involves intra-cytoplasmic interaction of GR/CS with 
transcription factors, resulting in the blockage of their activity and consequently hampering 
transcription of several inflammatory agents as cytokines and chemokines, simplifying  
synthesis of anti-inflammatory agents (Barnes, 1996).  
The importance of iCS in asthma treatment made the glucocorticoid receptors gene 
polymorphisms the obvious target of pharmacogenetic studies. However, despite the 
large number of researchers involved and the considerable funds devoted by both 
academic and industrial teams, only few polymorphisms have been discovered until now: 
Val→Asp641, that results in a three-fold lower binding affinity for dexamethasone, 
Val→Ile729 - with four-fold decrease in dexamethasone activity and Asn→Ser363 that 
results in higher activity to exogenous corticosteroids (Hurley et al., 1991; Malchof et al., 
1993; Huizenga et al., 1998). From published studies we know, that patients with GR gene 
polymorphisms Val→Asp641 and Val→Ile729 may be predisposed to a relatively 
decreased response to CS therapy (Koper et al., 1997; Lane et al., 1994). A three marker 
long haplotype G-A-T  (frequency 23% in general population; G allele - BclI SNP, A allele - 
intron B 33389, T allele - intron B 33388) was described in 2004 by Stevens and coworkers. 
It is associated with enhanced GC sensitivity measured as low postdexamethasone 
cortisol (frequency 41%). Subjects homozygous for G-A-T had over twofold FEV1 
improvement after CS treatment compared to heterozygous or non-G-A-T haplotypes 
(Tantisira et al., 2004). 
However, all these studies have not demonstrated a correlation between GR polymorphisms 
and corticosteroid resistance in asthma. Corticosteroid resistance does not seem to be 
dependent on a single GR gene polymorphism.  
2.3.2 Polymorphisms of the CRHR1 gene (corticotropin releasing hormone receptor 
type 1) 
In contrast to the GR gene polymorphism studies, CRHR1 investigations seem to yield 
more promising results. The CRHR1 gene is the major receptor for corticotropin that in 
turn is the key regulator of corticosteroids synthesis and catecholamine production.  
The gene for CRHR1 is located on chromosome 17q12-22, in the genomic region linked to 
asthma in a genome-wide-screen (Zandi et al., 2001). Most important data came  
from studies by Tantisira et al (Tantisira et al., 2004) that analyzed 14 genes connected 
with biological pathways of corticosteroids in three large groups of patients. Study 
participants were recruited from several other clinical trials studying the use of inhaled 
corticosteroids in asthma. The first group consisted of 470 adult individuals and was 
encoded AD (Adult Study), the second included 336 adult patients - ACRN (Asthma 
Clinical Research Network), and the third one included 311 children from CAMP 
(Childhood Asthma Management Program). This project revealed a significant correlation 
between lung function improvement after inhaled corticosteroid therapy and SNPs 
(rs1876828, rs242939 and rs242941) and haplotype occurrence within the CRHR1 gene, 
especially rs242941 (G→T, intron located) polymorphism, in all populations. In the AD 
population homozygous individuals with this polymorphism had average FEV1 
improvement, higher than homozygous patients lacking this SNP. Similar results were 
obtained for the paediatric population that was studied. These data can contribute to our 
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understanding of the diverse patient reactions to iCS treatment but further investigation is 
still necessary.   
2.3.3 Polymorphisms of the TBX21 gene (T-box expressed in T cells) 
Another gene modulating inhaled corticosteroids action is TBX21 that encodes T-bet 
transcription factor (Tantisira et al., 2004). It plays an important role in balancing 
lymphocyte subpopulations, enhancing Th1 and inhibiting Th2 clone formation. TBX21 
knockout mice develop bronchial hyperresponsiveness, enhanced airway eosinophilia and 
faster airway remodelling (Finotto et al., 2002) proving that TBX21 is crucial for asthma 
protection. 
So far one clinically important SNP, His→Glu33 (H33Q), was found within this gene’s 
area in mice. Cellular models suggest that the H33Q allele can activate Th1 cytokine 
production (including interferon Ǆ – INFǄ) that in turn decreases Th2 cytokine synthesis 
providing a stable protection against asthma and allergy development. Surprisingly 
enough, it has been demonstrated that corticosteroids are able to inhibit T-bet induction 
(Refojo et al., 2003) resulting in Th2 domination. These findings still require a direct in 
vivo confirmation. 
Studies in children (CAMP population) showed 4.5% occurrence in general population of 
homozygous Glu33 individuals. The presence of even one copy of this allele in subjects 
treated with iCS was associated with a significant decrease in airway hyperresponsiveness 
(measured as PC20) as compared to His33His homozygous subjects and individuals not iCS-
treated (Tantisira et al., 2004).  
2.3.4 Polymorphisms of the FCER2 gene (Fc fragment of IgE, low affinity II, receptor 
for (CD23)) 
The FCER2 gene encodes a protein, which is the low-affinity receptor for IgE and a key 
molecule for B-cell activation and growth. FCER2 gene polymorphism was predicted to 
bronchial hypperresponsiveness and IgE-mediated allergic diseases. Within this gene three 
SNPs have been described, all connected to higher risk of severe asthma and asthma 
exacerbations in spite of inhaled corticosteroids therapy. The polymorphism 2206T→C 
occurs relatively often (allelic frequency 0.26 in Caucasians and 0.44 in black population) 
and was carefully analyzed for potential association to inhaled corticosteroids therapy 
response (Tantisira et al., 2007). The presence of the C allele increases three- to four-fold the 
risk of severe asthma exacerbations. This effect was confirmed both in Afro-American and 
Caucasian individuals being under iCS therapy.     
2.3.5 Polymorphism of AC9 gene (cyclase adenylate 9) 
Although adenylate cyclase is activated via the ǃ2-adrenoreceptor it may also influence 
inhaled corticosteroids reaction. Individuals carrying the polymorphism Ile→Met 772 
demonstrate increased bronchial dilatation after SABA when treated with corticosteroids 
compared to wild-type individuals (isoleucine in 772 position) (Tantisira et al., 2005). This 
substitution results in a loss of function. Met772 has lower basic as well as beta2-mediated 
adenylyl cyclase activities compared to Ile772.  
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Gene  
Chromosomal 
location 
Polymorphism with potential pharmacogenetic 
consequences during iCS therapy  
CRHR1 17q12-22 rs242941 (G→T, intron) 
TBX21 17q21.32 His→Glu33 (H33Q) 
FCER2 19p13.3 2206T→C 
AC9 16p13.3-13.2 Ile→Met 772 
Table 2. List of gene polymorphism examples that could have pharmacogenetic 
consequences during corticosteroids therapy  
2.4 Pharmacogenetics of anticholinergic treatment  
2.4.1 Polymorphisms of the muscarinic receptor 
Anticholinergics are used mainly in chronic obstructive pulmonary disease (COPD) but 
sometimes also in asthma as second line bronchodilators. Anticholinergics are antagonists of 
muscarinic receptors: M1, M2 and M3. SNPs have been found in coding regions of M2 and 
M3 receptors (Fenech, 2001). The expression of M2 and M3 receptors is dependent on 
transcription regulation in the gene promoter region and polymorphisms have been 
demonstrated in both promoter regions (Fenech, 2004; Donfack, 2003). Furthermore 
different expression of M2 receptor may be related to various number of dinucleotide CA 
repetitions in gene promoter region. None of these changes has been investigated in relation 
to bronchodilation in asthma or COPD yet.  
3. Conclusions 
Genome analysis, candidate gene studies and SNP investigation represent a new approach 
to pharmacological treatment in all chronic diseases. Genetically defined differences 
combined with clinical phenotyping lead to treatment personalization. At this point 
“personalization” means selecting different treatment regimens for different groups of 
patients. The more knowledge on pharmacogenetics and general genetics we have, the 
smaller these groups are likely to be.  
iCS remain the mainstream therapy in asthma. Despite intensive research in this field there 
is only one biological treatment available for asthma and allergy (anti-IgE monoclonal 
antibody). Several other have been suggested and underwent pre-clinical or clinical tests, 
but to prove either their effectiveness and safety.   
All the studies presented in this chapter have aimed at the identification and 
characterization of subgroups of asthmatic patients that will derive optimal therapy benefit 
while minimizing or eliminating drug side effects. The ultimate goal in the 
pharmacogenetics of antiasthmatic medication is to enable the optimization of individual 
therapies from the very start, maximizing efficacy without exposing patients to side effects. 
That would also significantly improve patient’s treatment compliance. The amount of clear 
data from pharmacogenetics of antiasthmatic drugs is still limited due, among others, to the 
vast number of genotype variants in different populations. 
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Combined research of the past decade seem to suggests that either asthma has several 
phenotypes distinct in terms of inflammatory mechanisms (eosinophilic versus neutrophilic, 
IL-17 dependent vs non-dependent etc.) or “asthma” is rather a group of respiratory 
diseases with similar symptomatology than a uniform disease. Computerized multivariate 
analysis has to be employed in the process of defining clinically relevant disease phenotypes 
of asthma before effective pharmacogenetic research can be undertaken.  
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